摘要
有许多临床问题,即使是训练有素的医生也不容易回答。常用的诊断工具,是以评估认知功能障碍的神经退行性疾病为基础建立的临床标准。然而,疾病之间的鉴别诊断是困难的,特别是在早期阶段或非典型变种。当它仍然有可能使用一个适当的治疗时,这尤为重要。 为了解决这个问题,医生需要获得诊断测试的军工厂,如神经功能成像,允许更高的特异性临床评价。然而,诊断测试的可靠性从一个到下一个可能会有所不同,因此,一个给定的调查的诊断的有效性,必须估计通过从“真实”标准的“金标准”或基准测试比较获得的结果。虽然病理分析在广泛的疾病中被认为是的金标准,但是它不能被应用到神经系统过程。其他的方法可以提供解决方案,包括临床患者随访,创建一个数据银行或使用计算机辅助诊断算法。 在这篇文章中,我们讨论了与诊断效度分析相关不同的方法程序的发展和以使用碘-123-碘氟烷-单光子发射计算机化断层显像为基础介绍的运动障碍患者研究的一个自身经历。本章的目的是考虑到特定的神经退行性疾病的问题,从医生的角度来看探讨问题。
关键词: 阿尔茨海默病,计算机辅助诊断系统,痴呆,诊断准确,机器学习,神经成像,支持向量机。
Current Alzheimer Research
Title:Diagnosis of Neurodegenerative Diseases: The Clinical Approach
Volume: 13 Issue: 5
Author(s): Manuel Gómez-Río, Manuel Moreno Caballero, Juan Manuel Górriz Sáez and Adolfo Mínguez-Castellanos
Affiliation:
关键词: 阿尔茨海默病,计算机辅助诊断系统,痴呆,诊断准确,机器学习,神经成像,支持向量机。
摘要: There are a number of clinical questions for which there are no easy answers, even for welltrained doctors. The diagnostic tool commonly used to assess cognitive impairment in neurodegenerative diseases is based on established clinical criteria. However, the differential diagnosis between disorders can be difficult, especially in early phases or atypical variants. This takes on particular importance when it is still possible to use an appropriate treatment.
To solve this problem, physicians need to have access to an arsenal of diagnostic tests, such as neurofunctional imaging, that allow higher specificity in clinical assessment. However, the reliability of diagnostic tests may vary from one to the next, so the diagnostic validity of a given investigation must be estimated by comparing the results obtained from “true” criteria to the “gold standard” or reference test. While pathological analysis is considered to be the gold standard in a wide spectrum of diseases, it cannot be applied to neurological processes. Other approaches could provide solutions, including clinical patient follow-up, creation of a data bank or use of computer-aided diagnostic algorithms.
In this article, we discuss the development of different methodological procedures related to analysis of diagnostic validity and present an example from our own experience based on the use of I-123-ioflupane-SPECT in the study of patients with movement disorders. The aim of this chapter is to approach the problem of diagnosis from the point of view of the clinician, taking into account specific aspects of neurodegenerative disease.
Export Options
About this article
Cite this article as:
Manuel Gómez-Río, Manuel Moreno Caballero, Juan Manuel Górriz Sáez and Adolfo Mínguez-Castellanos , Diagnosis of Neurodegenerative Diseases: The Clinical Approach, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116141603
DOI https://dx.doi.org/10.2174/1567205013666151116141603 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Overlapping Syndromes of the Pick Complex
Current Alzheimer Research Conference Report: 10th Clinical Trials on Alzheimer's Disease (CTAD), Boston MA, USA, November 1-4, 2017
CNS & Neurological Disorders - Drug Targets Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Proteoglycans and Glycosaminoglycans in Misfolded Proteins Formation in Alzheimer's Disease
Protein & Peptide Letters Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training
Current Alzheimer Research Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Denervation of the Olfactory Bulb Leads to Decreased Aβ Plaque Load in a Transgenic Mouse Model of Alzheimer’ s Disease
Current Alzheimer Research The Possible Involvement of HLA Class III Haplotype (RAGE, HSP70 and TNF Genes) in Alzheimer's Disease
Current Alzheimer Research Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology The Cytokine Network in HIV Infection
Current Molecular Medicine Extra Virgin Olive Oils Polyphenols: Biological Activities
Current Pharmaceutical Design Determinants of Paraoxonase 1 Status: Genes, Drugs and Nutrition
Current Medicinal Chemistry Searching for Disease-Modifying Drugs in AD: Can We Combine Neuropsychological Tools with Biological Markers?
CNS & Neurological Disorders - Drug Targets